Efficacy and Safety of Qili Qiangxin Capsule on Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis of 35 Randomized Controlled Trials
Objective: Qili Qiangxin Capsule (QQC), a Chinese patent medicine, is clinically effective in treating dilated cardiomyopathy (DCM). However, the meta-analysis of QCC combined with conventional western medicine (CWM) on DCM remains unexplored. This study aimed to systematically evaluate the efficacy...
Main Authors: | Jingjing Wei, Bin Li, Xinlu Wang, Xingyuan Li, Yucai Hu, Lijie Qiao, Cheng Zhou, Peng Yu, Tianqing Sang, Mingjun Zhu, Yongxia Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.893602/full |
Similar Items
-
Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis
by: Qian Xiang, et al.
Published: (2022-04-01) -
Qili Qiangxin capsules for chronic heart failure: A GRADE-assessed clinical evidence and preclinical mechanism
by: Xiaoxiao Xing, et al.
Published: (2023-01-01) -
Qili Qiangxin (QLQX) capsule as a multi-functional traditional Chinese medicine in treating chronic heart failure (CHF): A review of ingredients, molecular, cellular, and pharmacological mechanisms
by: Tongxing Wang, et al.
Published: (2023-11-01) -
Efficacy and safety of Qili Qiangxin Capsule in the adjuvant treatment of ischemic cardiomyopathy with heart failure: a systematic review and meta-analysis
by: Yin Ziwei, et al.
Published: (2023-12-01) -
Network pharmacology and molecular docking analysis on Shenfu Qiangxin indicate mTOR is a potential target to treat heart failure
by: Peilin Zou, et al.
Published: (2024-03-01)